Drug Trial Radar · NCT01489228
Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease
Last checked: Nov 20, 2026Latest source record: Dec 21, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
230
Planned (sponsor's estimate)
Start
Jun 2011
Primary completion
Aug 2012
Study completion Dec 2013
Sponsor
- Lead sponsor
- Drugs for Neglected DiseasesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eisai Co., Ltd.
- First posted
- Dec 9, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of E1224, a pro-drug of ravuconazole, in individuals with chronic indeterminate Chagas disease recruited in research centres in Tarija and Cochabamba, Bolivia.
Conditions
- Chronic Chagas Disease, Indeterminate
Interventions
E1224Drug
100 mg tablets
BenznidazoleDrug
100mg tablets
PlaceboDrug
tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatmentTime frame: Day 65 (end of treatment)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas
Cochabamba, Cochabamba, Bolivia · Recruiting
Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas
Tarija, Tarija Department, Bolivia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.